{"id":"c788656aa5d1","type":"article","url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","title":"USPSTF: screening op lipidestoornissen bij kinderen en adolescenten","title_en":"Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.","category":"cholesterol","category_label":"Cholesterol","professions":["huisarts","internist"],"tags":["primaire-preventie"],"journal":"JAMA","doi":"10.1001/jama.2023.11330","source_url":"https://doi.org/10.1001/jama.2023.11330","authors":["Michael J Barry","Wanda K Nicholson","Michael Silverstein","David Chelmow","Tumaini Rucker Coker","Esa M Davis","Katrina E Donahue","Carlos Roberto Jaén","Li Li","Gbenga Ogedegbe","Goutham Rao","John M Ruiz","James Stevermer","Joel Tsevat","Sandra Millon Underwood"],"significance":7,"published":"2023-07-18","source_date":"2023-07-18","image":"","kennis":[],"congress":"","summary_en":"The USPSTF concluded that evidence is insufficient to determine whether universal lipid screening in children and adolescents improves health outcomes, maintaining the 'I' statement despite ongoing concern about familial hypercholesterolemia underdiagnosis.","created":"2026-07-03T10:30:29Z","updated":"2026-07-03T13:29:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De USPSTF concludeerde dat het bewijs onvoldoende is om te bepalen of universele lipidescreening bij kinderen de gezondheidsuitkomsten verbetert. Dit staat in contrast met de AAP-aanbeveling voor universele screening, wat het debat gaande houdt.","abstract_original":"IMPORTANCE: Familial hypercholesterolemia and multifactorial dyslipidemia are 2 conditions that cause abnormally high lipid levels in children, which can lead to premature cardiovascular events (eg, myocardial infarction and stroke) and death in adulthood. OBJECTIVE: The US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for lipid disorders in asymptomatic children and adolescents. POPULATION: Asymptomatic children and adolescents 20 years or younger without a known diagnosis of a lipid disorder. EVIDENCE ASSESSMENT: The USPSTF concludes that the current evidence is insufficient and the balance of benefits and harms for screening for lipid disorders in asymptomatic children and adolescents 20 years or younger cannot be determined. RECOMMENDATION: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents 20 years or younger. (I statement)."}